ATRIPLA 200 MG — DIN 02300699
EMTRICITABINE : 200 MG TENOFOVIR DISOPROXIL FUMARATE : 300 MG EFAVIRENZ : 600 MG · GILEAD SCIENCES, LLC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ATRIPLA?
ATRIPLA 200 MG contains EMTRICITABINE : 200 MG TENOFOVIR DISOPROXIL FUMARATE : 300 MG EFAVIRENZ : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02300699, held by GILEAD SCIENCES, LLC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 22-Dec-2021. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ATRIPLA used for?
ATRIPLA (efavirenz [EFV]/emtricitabine [FTC]/tenofovir disoproxil fumarate [TDF]) is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Emtricitabine, Tenofovir Disoproxil And Efavirenz in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Emtricitabine, Tenofovir Disoproxil And Efavirenz, across 9 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 1 | 1 | APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 1 | 1 | MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | Sourceable in Canada |
| GILEAD SCIENCES, LLC | 1 | 0 | ATRIPLA | No marketed DIN |
| LABORATOIRE RIVA INC. | 1 | 0 | RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Emtricitabine, Tenofovir Disoproxil And Efavirenz |
|---|---|
| ATC code | J05AR06 |
| AHFS class | 08:18.08.20 ; 08:18.08.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02300699 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2300699 |
| Brand name | ATRIPLA |
| Generic / active ingredient | EMTRICITABINE : 200 MG TENOFOVIR DISOPROXIL FUMARATE : 300 MG EFAVIRENZ : 600 MG |
| Market authorization holder | GILEAD SCIENCES, LLC |
| Health Canada schedule | Prescription |
| ATC code | J05AR06 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AR |
| Current status | CANCELLED POST MARKET |
| Status date | 22-Dec-2021 |
| Original market date | 2007-10-23 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 200 MG | TABLET | APOTEX INC | MARKETED | 02468247 |
| AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 200 MG | TABLET | AURO PHARMA INC | MARKETED | 02478404 |
| JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02519461 |
| MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02461412 |
| TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | 200 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02393549 |
| PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 600 MG | TABLET | PHARMASCIENCE INC | DORMANT | 02487284 |
| RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | 300 MG | TABLET | LABORATOIRE RIVA INC. | CANCELLED POST MARKET | 02518716 |
| SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02484676 |
2 · Same class — other molecules in ATC J05AR
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tenofovir Disoproxil And Emtricitabine | AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE · APO-EMTRICITABINE-TENOFOVIR · AURO-EMTRICITABINE-TENOFOVIR · JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · +6 more | 10 | 9 | Yes |
| Emtricitabine, Tenofovir Disoproxil And Efavirenz | APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · ATRIPLA · AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · +5 more | 9 | 5 | Yes |
| Lamivudine And Abacavir | APO-ABACAVIR-LAMIVUDINE · APO-ABACAVIR-LAMIVUDINE TABLETS · AURO-ABACAVIR/LAMIVUDINE · JAMP ABACAVIR / LAMIVUDINE · +5 more | 9 | 4 | Yes |
| Zidovudine And Lamivudine | APO-LAMIVUDINE-ZIDOVUDINE · AURO-LAMIVUDINE/ZIDOVUDINE · COMBIVIR · JAMP LAMIVUDINE / ZIDOVUDINE · +1 more | 5 | 3 | Yes |
| Lopinavir And Ritonavir | KALETRA | 4 | 3 | Yes |
| Emtricitabine, Tenofovir Alafenamide And Bictegravir | BIKTARVY | 2 | 2 | Yes |
| Emtricitabine And Tenofovir Alafenamide | DESCOVY | 2 | 2 | Yes |
| Emtricitabine, Tenofovir Alafenamide And Rilpivirine | ODEFSEY | 1 | 1 | Yes |
| Darunavir And Cobicistat | PREZCOBIX | 1 | 1 | Yes |
| Emtricitabine, Tenofovir Alafenamide, Elvitegravir And Cobicistat | GENVOYA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.